PM360

MAY 15, 2023

When a patient meets predetermined triggering criteria, a brand message appears in the EHR. For example, starting in 2015 at Ogilvy, I watched companies that had been using print materials in doctors’ offices begin switching to large electronic tablets in waiting and exams rooms that displayed information for multiple brands.

Marketing 52

Marketing Electronics Doctors Physicians 52

Impetus Digital

JANUARY 3, 2023

A couple of years ago, I first wrote about how social media’s role in the Pharma and healthcare sectors has been growing exponentially. In recent years, social media has evolved into an essential part of Pharma operations, for better or worse. . A version of this article was previously published on PharmaPhorum. Congress Coverage.

Media 52

Media Healthcare Healthcare Recruitment 52

Clarivate

APRIL 24, 2023

Health systems will buy or establish an insurance plan to serve as an extension of their continuum of care, a means of directing referral streams to increase revenue and securing control over clinical and formulary decisions for patients. In January 2023, VillageMD acquired Summit Health for $8.9

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

PM360

AUGUST 9, 2022

Then between 2005-2015, there were 110 global blockbuster launches, with a high concentration in specialty care and biologics. Due to COVID-19, leaders also face the challenge of rethinking global and regional supply chain resilience to manufacture and supply these therapies to patients.

Biopharma 69

Biopharma Marketing Healthcare Healthcare 69

Pharmaceutical Technology

SEPTEMBER 26, 2022

Both Sandoz and Novartis are internationally renowned pharma companies, with a combined 34 production facilities worldwide. Strong competition limits Sandoz's growth. On 30 September 2015, GSK agreed to pay $5.25bn for Novartis's vaccines business, while Novartis purchased GSK's oncology division for $16bn.

Competition 64

Competition Manufacturing Marketing Distribution 64

pharmaphorum

JANUARY 16, 2023

Even where there has been innovation, for example in cholesterol lowering with PCSK-9s and the siRNA treatment Leqvio, the vast majority of patients are on generic versions of medicines launched in the 1990s, and innovative medicines have not transformed the treatment paradigm.

FDA 91

FDA Healthcare Healthcare Medicine 91

pharmaphorum

OCTOBER 10, 2022

Teva’s last remaining Copaxone (glatiramer acetate) patent expired in Europe in February 2015 and the Commission said last March it was investigating whether the company acted lawfully in trying to delay the entry of lower-cost generic versions of the drug.

Competition 52

Competition Marketing Medicine Pharma 52

Pharmaceutical Technology

JULY 25, 2022

With decreasing margins on the horizon, pharma manufacturers have long shown an interest in specialty generics, which is only expected to rise in the future. But this also means potentially stiffer competition for chemical entities and small molecules in comparison to biosimilars, states Vasquez.

Manufacturing 119

Manufacturing Marketing Pharmaceutical FDA 119

Pharmaceutical Technology

OCTOBER 25, 2022

Understanding both the significant competitive advantages that FDC products can offer, and the difficulties and potential pitfalls associated with development and manufacturing of FDC drugs in oral solid dosage forms is a critical first step for companies exploring this approach. More FDC products flowing into pharma pipelines.

Manufacturing 52

Manufacturing Physicians Prescription FDA 52

Pharmaceutical Technology

JANUARY 25, 2023

Uptake of mobile healthcare, wearable devices and web-based technologies meant decentralised clinical trials made up 30% of overall trials in 2021 – an increase of 9% since 2015. Decentralisation will enable further expansion as researchers and patients connect across ever greater distances. The world of clinical trials is changing.

Pharma 59

Pharma Pharmaceutical Distribution Patients 59

Pharmaceutical Technology

JANUARY 25, 2023

Uptake of mobile healthcare, wearable devices and web-based technologies meant decentralised clinical trials made up 30% of overall trials in 2021 – an increase of 9% since 2015. Decentralisation will enable further expansion as researchers and patients connect across ever greater distances. The world of clinical trials is changing.

Pharma 52

Pharma Pharmaceutical Distribution Patients 52